Q2 Earnings Forecast for Korro Bio Issued By HC Wainwright

Korro Bio, Inc. (NASDAQ:KRRO) – HC Wainwright reduced their Q2 2026 earnings per share estimates for Korro Bio in a note issued to investors on Thursday, January 29th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per share of ($1.85) for the quarter, down from their prior estimate of ($1.67). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Korro Bio’s current full-year earnings is ($9.52) per share. HC Wainwright also issued estimates for Korro Bio’s Q3 2026 earnings at ($1.90) EPS, Q4 2026 earnings at ($1.95) EPS and FY2026 earnings at ($7.56) EPS.

A number of other equities research analysts have also commented on the stock. Cantor Fitzgerald lowered shares of Korro Bio from an “overweight” rating to a “neutral” rating in a report on Thursday, November 13th. Raymond James Financial restated a “market perform” rating on shares of Korro Bio in a research report on Wednesday, January 28th. Wall Street Zen lowered shares of Korro Bio from a “hold” rating to a “sell” rating in a report on Saturday, December 13th. Piper Sandler cut Korro Bio from an “overweight” rating to a “neutral” rating and set a $11.00 target price on the stock. in a research note on Thursday, November 13th. Finally, Chardan Capital upgraded Korro Bio from a “neutral” rating to a “buy” rating and set a $15.00 price target on the stock in a report on Thursday. Two analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $66.50.

Korro Bio Stock Performance

Shares of KRRO stock opened at $13.05 on Monday. The company has a market capitalization of $122.93 million, a P/E ratio of -1.39 and a beta of 2.99. Korro Bio has a fifty-two week low of $5.20 and a fifty-two week high of $55.89. The stock has a 50 day moving average price of $8.44 and a two-hundred day moving average price of $21.26.

Korro Bio (NASDAQ:KRRO) last issued its earnings results on Wednesday, November 12th. The company reported ($1.92) earnings per share for the quarter, beating the consensus estimate of ($2.61) by $0.69. Korro Bio had a negative return on equity of 68.87% and a negative net margin of 1,199.53%.The company had revenue of $1.09 million during the quarter, compared to analysts’ expectations of $0.41 million.

Hedge Funds Weigh In On Korro Bio

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Russell Investments Group Ltd. purchased a new stake in Korro Bio in the third quarter worth about $39,000. CWM LLC grew its holdings in shares of Korro Bio by 391.4% during the 3rd quarter. CWM LLC now owns 2,693 shares of the company’s stock worth $129,000 after acquiring an additional 2,145 shares during the period. PNC Financial Services Group Inc. bought a new position in shares of Korro Bio in the 3rd quarter worth approximately $140,000. Millennium Management LLC lifted its stake in shares of Korro Bio by 1.8% in the 3rd quarter. Millennium Management LLC now owns 260,333 shares of the company’s stock valued at $12,467,000 after purchasing an additional 4,650 shares during the period. Finally, Wealth Forward LLC purchased a new position in shares of Korro Bio in the 3rd quarter valued at approximately $240,000. Hedge funds and other institutional investors own 13.18% of the company’s stock.

About Korro Bio

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.